These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 25660215)

  • 1. Alternative therapies to address the unmet medical needs of patients with phenylketonuria.
    Blau N; Longo N
    Expert Opin Pharmacother; 2015 Apr; 16(6):791-800. PubMed ID: 25660215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term comparative effectiveness of pegvaliase versus standard of care comparators in adults with phenylketonuria.
    Zori R; Ahring K; Burton B; Pastores GM; Rutsch F; Jha A; Jurecki E; Rowell R; Harding C
    Mol Genet Metab; 2019; 128(1-2):92-101. PubMed ID: 31439512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up.
    Burton BK; Longo N; Vockley J; Grange DK; Harding CO; Decker C; Li M; Lau K; Rosen O; Larimore K; Thomas J;
    Mol Genet Metab; 2020 Aug; 130(4):239-246. PubMed ID: 32593547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation and PEGylation optimization of the therapeutic PEGylated phenylalanine ammonia lyase for the treatment of phenylketonuria.
    Bell SM; Wendt DJ; Zhang Y; Taylor TW; Long S; Tsuruda L; Zhao B; Laipis P; Fitzpatrick PA
    PLoS One; 2017; 12(3):e0173269. PubMed ID: 28282402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM).
    Thomas J; Levy H; Amato S; Vockley J; Zori R; Dimmock D; Harding CO; Bilder DA; Weng HH; Olbertz J; Merilainen M; Jiang J; Larimore K; Gupta S; Gu Z; Northrup H;
    Mol Genet Metab; 2018 May; 124(1):27-38. PubMed ID: 29653686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria.
    Sarkissian CN; Gámez A; Wang L; Charbonneau M; Fitzpatrick P; Lemontt JF; Zhao B; Vellard M; Bell SM; Henschell C; Lambert A; Tsuruda L; Stevens RC; Scriver CR
    Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20894-9. PubMed ID: 19095795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythrocyte-mediated delivery of phenylalanine ammonia lyase for the treatment of phenylketonuria in BTBR-Pah(enu2) mice.
    Rossi L; Pierigè F; Carducci C; Gabucci C; Pascucci T; Canonico B; Bell SM; Fitzpatrick PA; Leuzzi V; Magnani M
    J Control Release; 2014 Nov; 194():37-44. PubMed ID: 25151978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenylalanine ammonia lyase, enzyme substitution therapy for phenylketonuria, where are we now?
    Sarkissian CN; Gámez A
    Mol Genet Metab; 2005 Dec; 86 Suppl 1():S22-6. PubMed ID: 16165390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria.
    Zori R; Thomas JA; Shur N; Rizzo WB; Decker C; Rosen O; Li M; Schweighardt B; Larimore K; Longo N
    Mol Genet Metab; 2018 Nov; 125(3):217-227. PubMed ID: 30146451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial.
    Longo N; Harding CO; Burton BK; Grange DK; Vockley J; Wasserstein M; Rice GM; Dorenbaum A; Neuenburg JK; Musson DG; Gu Z; Sile S
    Lancet; 2014 Jul; 384(9937):37-44. PubMed ID: 24743000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenylalanine ammonia lyase (PAL): From discovery to enzyme substitution therapy for phenylketonuria.
    Levy HL; Sarkissian CN; Scriver CR
    Mol Genet Metab; 2018 Aug; 124(4):223-229. PubMed ID: 29941359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of pegylated forms of recombinant Rhodosporidium toruloides phenylalanine ammonia-lyase for the treatment of classical phenylketonuria.
    Gámez A; Sarkissian CN; Wang L; Kim W; Straub M; Patch MG; Chen L; Striepeke S; Fitzpatrick P; Lemontt JF; O'Neill C; Scriver CR; Stevens RC
    Mol Ther; 2005 Jun; 11(6):986-9. PubMed ID: 15922970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sapropterin: a review of its use in the treatment of primary hyperphenylalaninaemia.
    Sanford M; Keating GM
    Drugs; 2009; 69(4):461-76. PubMed ID: 19323589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new therapy prevents intellectual disability in mouse with phenylketonuria.
    Pascucci T; Rossi L; Colamartino M; Gabucci C; Carducci C; Valzania A; Sasso V; Bigini N; Pierigè F; Viscomi MT; Ventura R; Cabib S; Magnani M; Puglisi-Allegra S; Leuzzi V
    Mol Genet Metab; 2018 May; 124(1):39-49. PubMed ID: 29661557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction of sapropterin dihydrochloride as standard of care in patients with phenylketonuria.
    Vernon HJ; Koerner CB; Johnson MR; Bergner A; Hamosh A
    Mol Genet Metab; 2010 Jul; 100(3):229-33. PubMed ID: 20418136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose sapropterin dihydrochloride therapy improves monoamine neurotransmitter turnover in murine phenylketonuria (PKU).
    Winn SR; Scherer T; Thöny B; Harding CO
    Mol Genet Metab; 2016 Jan; 117(1):5-11. PubMed ID: 26653793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spotlight on sapropterin in primary hyperphenylalaninemia.
    Sanford M; Keating GM
    BioDrugs; 2009; 23(3):201-2. PubMed ID: 19627172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sapropterin dihydrochloride: a new drug and a new concept in the management of phenylketonuria.
    Trefz FK; Belanger-Quintana A
    Drugs Today (Barc); 2010 Aug; 46(8):589-600. PubMed ID: 20830319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of orally administered PEGylated phenylalanine ammonia lyase in mice for the treatment of Phenylketonuria.
    Sarkissian CN; Kang TS; Gámez A; Scriver CR; Stevens RC
    Mol Genet Metab; 2011 Nov; 104(3):249-54. PubMed ID: 21803624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Silk-Based Platform to Stabilize Phenylalanine Ammonia-lyase for Orally Administered Enzyme Replacement Therapy.
    d'Amone L; Trivedi VD; Nair NU; Omenetto FG
    Mol Pharm; 2022 Dec; 19(12):4625-4630. PubMed ID: 35862031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.